Page 211 - 2019_02-Haematologica-web

Anti-HLA antibodies with complementary and synergistic interaction
28. Jones CG, Pechauer SM, Curtis BR, Bougie DW, Aster RH, Padmanabhan A. IgG in normal plasma inhibits HIT antibody- mediated platelet activation: Implications for plasma exchange in HIT. Blood. 2018;131(6):703–706.
29. Padmanabhan A, Jones CG, Pechauer SM, et al. IVIg for treatment of severe refractory heparin-induced thrombocytopenia. Chest. 2017;152(3):478-485.
30. Ugurlar D, Howes SC, Kreuk B De, et al. Structures of C1-IgG1 provide insights into howdanger pattern recognition activates complement. Science. 2018;359(6377):794- 797.
31. Wang G, de Jong RN, van den Bremer ETJ, et al. Molecular basis of assembly and acti- vation of complement component C1 in complex with immunoglobulin G1 and antigen. Mol Cell. 2016;63(1):135-145.
32. Dekkers G, Plomp R, Koeleman CAM, et al. Multi-level glyco-engineering tech- niques to generate IgG with defined Fc-gly-
cans. Sci Rep. 2016;6(36964):1-12.
33. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;
5:520.
34. Vassallo RR, Fung M, Rebulla P, et al. Utility
placebo-controlled trial of intravenous gammaglobulin in alloimmunized throm- bocytopenic patients. Blood. 1990; 75(1):313-316.
38. Thajudeen B, Sussman A, Bracamonte E. A case of atypical hemolytic uremic syn- drome successfully treated with eculizum- ab. Case Rep Nephrol Urol. 2013;3(2):139-
of cross-matched platelet transfusions in
patients with hypoproliferative thrombo-
cytopenia: A systematic review. 146.
Transfusion 2014;54(4):1180-1191.
35. Basta M, Dalakas MC. High-dose intra- venous immunoglobulin exerts its benefi- cial effect in patients with dermatomyositis by blocking endomysial deposition of acti- vated complement fragments. J Clin Invest.
1994;94(5):1729-1735.
36. Kazatchkine M, Kaveri S.
Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001; 345(10):747-755.
37. Kickler T, Braine HG, Piantadosi S, Ness PM, Herman JH, Rothko K. A randomized,
39. Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J kidney Dis. 2012;59(5):707-710.
40. Vo PT, Purev E, West KA, et al. Complement inhibition using eculizumab overcomes platelet transfusion refractori- ness in allo-immunized patients receiving HLA mismatched platelets. Blood. 2016;128(22):3840.
41. Huang Y. Evolution of compstatin family as therapeutic complement inhibitors. Expert Opin Drug Discov. 2018;13(5):435-444.
haematologica | 2019; 104(2)
415